Your browser doesn't support javascript.
loading
Design of Beta-2 Microglobulin Adsorbent Protein Nanoparticles.
Miller, Justin E; Castells-Graells, Roger; Arbing, Mark A; Munoz, Aldo; Jiang, Yi-Xiao; Espinoza, Charlize T; Nguyen, Brian; Moroz, Paul; Yeates, Todd O.
Afiliación
  • Miller JE; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA.
  • Castells-Graells R; UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.
  • Arbing MA; UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, CA 90095, USA.
  • Munoz A; Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
  • Jiang YX; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA.
  • Espinoza CT; Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
  • Nguyen B; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA.
  • Moroz P; School of Medicine, Curtin University, Perth, WA 6845, Australia.
  • Yeates TO; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA.
Biomolecules ; 13(7)2023 07 14.
Article en En | MEDLINE | ID: mdl-37509158
Beta-2 microglobulin (B2M) is an immune system protein that is found on the surface of all nucleated human cells. B2M is naturally shed from cell surfaces into the plasma, followed by renal excretion. In patients with impaired renal function, B2M will accumulate in organs and tissues leading to significantly reduced life expectancy and quality of life. While current hemodialysis methods have been successful in managing electrolyte as well as small and large molecule disturbances arising in chronic renal failure, they have shown only modest success in managing plasma levels of B2M and similar sized proteins, while sparing important proteins such as albumin. We describe a systematic protein design effort aimed at adding the ability to selectively remove specific, undesired waste proteins such as B2M from the plasma of chronic renal failure patients. A novel nanoparticle built using a tetrahedral protein assembly as a scaffold that presents 12 copies of a B2M-binding nanobody is described. The designed nanoparticle binds specifically to B2M through protein-protein interactions with nanomolar binding affinity (~4.2 nM). Notably, binding to the nanoparticle increases the effective size of B2M by over 50-fold, offering a potential selective avenue for separation based on size. We present data to support the potential utility of such a nanoparticle for removing B2M from plasma by either size-based filtration or by polyvalent binding to a stationary matrix under blood flow conditions. Such applications could address current shortcomings in the management of problematic mid-sized proteins in chronic renal failure patients.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Fallo Renal Crónico Límite: Humans Idioma: En Revista: Biomolecules Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Fallo Renal Crónico Límite: Humans Idioma: En Revista: Biomolecules Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos